Agenus (NASDAQ:AGEN) Upgraded to Hold at StockNews.com

Agenus (NASDAQ:AGEN) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday.

A number of other research analysts have also recently issued reports on the stock. Robert W. Baird lowered their price target on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a report on Tuesday. Six analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.75.

Agenus Price Performance

NASDAQ AGEN traded down $0.06 during trading hours on Friday, reaching $1.61. 733,912 shares of the company’s stock traded hands, compared to its average volume of 610,897. Agenus has a 52-week low of $1.61 and a 52-week high of $19.69. The firm has a market cap of $37.77 million, a PE ratio of -0.14 and a beta of 1.23. The firm has a 50-day simple moving average of $3.01 and a 200 day simple moving average of $3.67.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The business had revenue of $26.84 million for the quarter, compared to analysts’ expectations of $30.09 million. Sell-side analysts forecast that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Deutsche Bank AG grew its stake in shares of Agenus by 538.4% in the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 51,566 shares during the period. Corton Capital Inc. bought a new stake in shares of Agenus in the fourth quarter worth approximately $36,000. Bank of America Corp DE grew its stake in shares of Agenus by 34.0% in the fourth quarter. Bank of America Corp DE now owns 107,123 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 27,157 shares during the period. Jane Street Group LLC grew its stake in shares of Agenus by 97.6% in the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock worth $290,000 after acquiring an additional 52,215 shares during the period. Finally, B. Riley Financial Inc. bought a new stake in shares of Agenus in the fourth quarter worth approximately $2,074,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.